ClinicalTrials.gg
RecruitingNCT03895541ELASTOCARDIO2Updated Oct 9, 2026

Noninvasive Elastography Evaluation of Myocardial Stiffness in Elderly Patients With Isolated Diastolic Heart Failure: New Diagnostic Tool?

An interventional study of SuperSonic image in Cardiovascular Diseases in Old Age, sponsored by French Cardiology Society. Recruiting at 1 site in France. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by French Cardiology Society · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Jan 2020; still recruiting 6 years 9 months later.
Updated Oct 9, 2026Primary completion movedStudy completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
140
Allocation
Not applicable
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 16 studies in Heart Failure by French Cardiology Society — 3 open to participants now, 3 under way, none of them phase 3. Heart Failure · French Cardiology Society.

Started
2020
with 1 other
No phase
8 of 16
2 open now
Registered
11th of 16
by date

Among the 16 studies in Heart Failure by French Cardiology Society, this one is one of 2 that started in 2020, is one of 8 with no phase, and was the 11th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

3 of the 16 studies in Heart Failure by French Cardiology Society are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Heart Failure by French Cardiology Society, or all of them as a file.
02

Study summary

The new approach propose in this protocol is based on ultrafast ultrasound and remote palpation of tissue by ultrasonic radiation pressure. Ultrafast ultrasound of biological tissues is based on an innovative ultrasound imaging approach that can image very fast soft tissue events at a rate of several thousands of frames per second and provide quantitative mapping of the elasticity of the tissues. This current project aims is to focus on myocardial rigidity in diastole to better assess the function of the heart failure.

Read the detailed description

Diastolic heart failure or heart failure with preserved systolic function is the leading cause of heart failure in elderly subjects (more than 2/3 of heart failure in subjects over 60 years). Its main etiology is high blood pressure. Diagnosis of diastolic heart failure remains controversial in clinical practice. It is based on ultrasound and biological criteria. These are mainly acute edema of the lung for patients with preserved Ejection Fraction and high Brain Natriuretic Peptid. It is now recognized that the "primum movens" of this type of heart failure is the increase in myocardial stiffness secondary to left ventricular hypertrophy. The noninvasive evaluation of this parameter would allow a more accurate and reliable diagnosis since it does not depend on the loading conditions, unlike the heart failure and the trans-mitral Doppler). However, the absence of a non-invasive tool for the direct evaluation of diastolic (so-called passive) rigidity prevents the use of this diagnostic parameter. Investigators propose here to non-invasively evaluate the myocardial stiffness in the elderly patient with diastolic heart failure thanks to a new imaging tool using an innovative ultrasonic technology, the ultrafast-echo associated with its elastographic mode "ShearWave Imaging". Investigators have been working for several years in collaboration with the Langevin Institute on this technology, which has recently been validated on experimental models. Its principle is based on the creation of a shear wave from a standard ultrasound probe and the calculation of the velocity of this wave thanks to the very high temporal resolution of the ultrasound system, this speed being correlated to the myocardial rigidity. The human study was recently made possible by the development of a phased array probe with the ability to work with the elastography mode ("ShearWave Imaging").

03

Conditions studied

  • Cardiovascular Diseases in Old Age

Browse trials for

Keywords

  • heart failure
  • myocardial rigidity
  • new diagnosis
  • ultrasound imaging
04

Who can participate

The criteria were revised on the registry on Oct 9, 2026. See what changed

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

General inclusion criteria:

  • Subjects who have received information about the study and signed the form.
  • Beneficiary of a social security scheme.
  • Age ≥18 years.
  • Hospitalization in a cardiology department.

Specific inclusion criteria:

HFpEF group (preserved ):

  • Left ventricular ejection fraction (LVEF) ≥50%.
  • BNP ≥35 pg/mL or NT-proBNP ≥135 pg/mL.
  • At least one of the following:

    • Echocardiographic structural alteration: left atrial dilatation (biplane volume ≥34 mL/m²) or left ventricular hypertrophy (LV mass index ≥115 g/m² in men or ≥95 g/m² in women).
    • Echocardiographic functional alteration: criteria of diastolic dysfunction including E >50 cm/s, mean septal-lateral e' \<9 cm/s, E/e' ≥13, or peak tricuspid regurgitation velocity ≥2.8 m/s.
  • For 25 patients: documented cardiac amyloidosis.

HFmrEF group (moderately reduced left ventricular ejection fraction):

  • LVEF between 40% and 49%.
  • BNP ≥35 pg/mL or NT-proBNP ≥135 pg/mL.
  • At least one of the following:

    • Echocardiographic structural alteration: left atrial dilatation (biplane volume ≥34 mL/m²) or left ventricular hypertrophy (LV mass index ≥115 g/m² in men or ≥95 g/m² in women).
    • Echocardiographic functional alteration: criteria of diastolic dysfunction including mean septal-lateral e' \<9 cm/s, E/e' ≥13, or peak tricuspid regurgitation velocity ≥2.8 m/s.

HFrEF group (reduced left ventricular ejection fraction):

- Diagnosis of heart failure with reduced ejection fraction according to the ESC Guidelines.

  • Presence of symptoms of heart failure.
  • Presence of clinical signs of heart failure.
  • LVEF \<40%.

General exclusion criteria:

  • Pregnancy.
  • Poor echogenicity.
  • Allergy to echocardiography gel.

Specific exclusion criteria:

HFpEF group:

  • Associated pulmonary disease.
  • Regional wall motion abnormality.

HFmrEF group:

- Associated pulmonary disease.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
140 participants (estimated)

Study arms

  • Other
    Stratification

    All patient will have the same intervention. They will be stratified regarding their degree of heart failure gravity. * HFpEF : 80 patients (including 25 with cardiac amyloidosis) * HFmrEF : 30 patients * HFrEF : 30 patients

    Diagnostic Test: SuperSonic image

Interventions

  • Diagnostic testSuperSonic image

    3 examen performed assessed to compared evaluation type: Cardiac magnetic resonance imaging, standard ultrasound imaging and ultrafast imaging

06

What researchers measure

Primary outcomes

  1. Myocardial stiffness assessment by elastography

    Assessment of myocardial stiffness using non-invasive ultrasound elastography, and comparison of the elastography-derived myocardial stiffness parameters with conventional echocardiographic and biological parameters used for the diagnosis of diastolic heart failure.

    Time frame: Day 1

Secondary outcomes

  1. Norms estimation of myocardial rigidity

    Estimation of physiological and pathological norms of myocardial rigidity by elastography to detect and diagnose heart failure according to the left ventricular ejection fraction phenotype (HFpEF, HFmrEF and HFrEF).

    Time frame: Day 1

  2. Characterization of myocardial stiffness in patients with HFpEF

    Evaluation of myocardial stiffness assessed by elastography in a larger population of patients with heart failure with preserved ejection fraction (LVEF ≥50%), including characterization of patients with and without documented cardiac amyloidosis.

    Time frame: Day 1

  3. Diagnostic parameters of SWI in cardiac amyloidosis

    Evaluation of differences in myocardial stiffness and other ShearWave Imaging -derived parameters between patients with HFpEF with and without documented cardiac amyloidosis, in order to further characterize the diagnostic performance of ShearWave Imaging

    Time frame: Day 1

  4. Safety of cardiac elastography

    patient monitoring (electrocardiogram scope and constants every10 min) for 30 minutes post-examination associated with a "comfort questionnaire" to be completed by the patient after the examination

    Time frame: Day 1

07

Study locations

1 of 1 sites recruiting
  • Emmanuel MESSAS
    Paris, 75015, France
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2020 (actual). Primary completion is estimated for Dec 2026, 83 months after the start.

Of 1,119 non-industry interventional studies with no phase under Heart Failure, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's planned 83 months is above that.

Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 9, 2026: primary completion Dec 2025 → Dec 2026 and completion Dec 2025 → Dec 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 28, 2019
First posted
Mar 29, 2019
StartActual
Jan 24, 2020
Primary completionEst.
Dec 31, 2026was Dec 2025
CompletionEst.
Dec 31, 2026was Dec 2025
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 31, 2025→Dec 31, 2026
Oct 9, 2026
Study completion
Dec 31, 2025→Dec 31, 2026
Oct 9, 2026
Enrollment
90→140
Oct 9, 2026
Eligibility
Minimum age 60 Years→18 Years; Maximum age 80 Years→100 Years; Criteria largely rewritten (37 changes)
What changed in the criteria
  • EditedGlobal Inclusion CriteriaGeneral inclusion criteria:
  • RemovedHospitalization in cardiology services for acute pulmonary edema during heart failure
  • RemovedNatriuretic peptide type B ≥35 pg/ml
  • RemovedEchocardiographic structural alteration
  • AddedSubjects who have received information about the study and signed the informed consent form.
  • AddedBeneficiary of a social security scheme.
  • AddedAge ≥18 years.
  • AddedHospitalization in a cardiology department.
  • AddedHFpEF group (preserved left ventricular ejection fraction):
  • EditedGroup "preserved LVEF": Left ventricular Ejection Fractionejection fraction (LVEF) ≥50%.
  • AddedBNP ≥35 pg/mL or NT-proBNP ≥135 pg/mL.
  • AddedAt least one of the following:
  • AddedEchocardiographic structural alteration: left atrial dilatation (biplane volume ≥34 mL/m²) or left ventricular hypertrophy (LV mass index ≥115 g/m² in men or ≥95 g/m² in women).
  • AddedEchocardiographic functional alteration: criteria of diastolic dysfunction including E >50 cm/s, mean septal-lateral e' <9 cm/s, E/e' ≥13, or peak tricuspid regurgitation velocity ≥2.8 m/s.
  • AddedFor 25 patients: documented cardiac amyloidosis.
  • AddedHFmrEF group (moderately reduced left ventricular ejection fraction):
  • EditedGroup "moderate alteration of LVEF": Left ventricular Ejection Fraction between 40% and 49%.
  • RemovedGroup "Systolic heart failure": Left ventricular Ejection Fraction< 40%
  • AddedBNP ≥35 pg/mL or NT-proBNP ≥135 pg/mL.
  • AddedAt least one of the following:
  • AddedEchocardiographic structural alteration: left atrial dilatation (biplane volume ≥34 mL/m²) or left ventricular hypertrophy (LV mass index ≥115 g/m² in men or ≥95 g/m² in women).
  • AddedEchocardiographic functional alteration: criteria of diastolic dysfunction including mean septal-lateral e' <9 cm/s, E/e' ≥13, or peak tricuspid regurgitation velocity ≥2.8 m/s.
  • AddedHFrEF group (reduced left ventricular ejection fraction):
  • Added- Diagnosis of heart failure with reduced ejection fraction according to the ESC Guidelines.
  • AddedPresence of symptoms of heart failure.
  • AddedPresence of clinical signs of heart failure.
  • AddedLVEF <40%.
  • EditedGlobal Exclusion CriteriaGeneral exclusion criteria:
  • RemovedOther associated lung pathology
  • RemovedOther heart disease
  • EditedContraindicationAllergy to MRI or echocardiography gel.
  • AddedSpecific exclusion criteria:
  • AddedHFpEF group:
  • AddedAssociated pulmonary disease.
  • AddedRegional wall motion abnormality.
  • AddedHFmrEF group:
  • Added- Associated pulmonary disease.
Oct 9, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedMyocardial rigiditystiffness assessment by elastographyTime frame: Day 1
Oct 9, 2026
Secondary outcomes
2 added, 1 description edited
What changed in the outcomes
  • AddedCharacterization of myocardial stiffness in patients with HFpEFTime frame: Day 1
  • AddedDiagnostic parameters of SWI in cardiac amyloidosisTime frame: Day 1
  • DescriptionNorms estimation of myocardial rigidity: how it is measured was reworded
Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    Primary completion Dec 31, 2025→Dec 31, 2026
    Study completion Dec 31, 2025→Dec 31, 2026
    Enrollment 90→140
    Eligibility Minimum age 60 Years→18 Years; Maximum age 80 Years→100 Years; Criteria largely rewritten (37 changes)
    What changed in the criteria
    • EditedGlobal Inclusion CriteriaGeneral inclusion criteria:
    • RemovedHospitalization in cardiology services for acute pulmonary edema during heart failure
    • RemovedNatriuretic peptide type B ≥35 pg/ml
    • RemovedEchocardiographic structural alteration
    • AddedSubjects who have received information about the study and signed the informed consent form.
    • AddedBeneficiary of a social security scheme.
    • AddedAge ≥18 years.
    • AddedHospitalization in a cardiology department.
    • AddedHFpEF group (preserved left ventricular ejection fraction):
    • EditedGroup "preserved LVEF": Left ventricular Ejection Fractionejection fraction (LVEF) ≥50%.
    • AddedBNP ≥35 pg/mL or NT-proBNP ≥135 pg/mL.
    • AddedAt least one of the following:
    • AddedEchocardiographic structural alteration: left atrial dilatation (biplane volume ≥34 mL/m²) or left ventricular hypertrophy (LV mass index ≥115 g/m² in men or ≥95 g/m² in women).
    • AddedEchocardiographic functional alteration: criteria of diastolic dysfunction including E >50 cm/s, mean septal-lateral e' <9 cm/s, E/e' ≥13, or peak tricuspid regurgitation velocity ≥2.8 m/s.
    • AddedFor 25 patients: documented cardiac amyloidosis.
    • AddedHFmrEF group (moderately reduced left ventricular ejection fraction):
    • EditedGroup "moderate alteration of LVEF": Left ventricular Ejection Fraction between 40% and 49%.
    • RemovedGroup "Systolic heart failure": Left ventricular Ejection Fraction< 40%
    • AddedBNP ≥35 pg/mL or NT-proBNP ≥135 pg/mL.
    • AddedAt least one of the following:
    • AddedEchocardiographic structural alteration: left atrial dilatation (biplane volume ≥34 mL/m²) or left ventricular hypertrophy (LV mass index ≥115 g/m² in men or ≥95 g/m² in women).
    • AddedEchocardiographic functional alteration: criteria of diastolic dysfunction including mean septal-lateral e' <9 cm/s, E/e' ≥13, or peak tricuspid regurgitation velocity ≥2.8 m/s.
    • AddedHFrEF group (reduced left ventricular ejection fraction):
    • Added- Diagnosis of heart failure with reduced ejection fraction according to the ESC Guidelines.
    • AddedPresence of symptoms of heart failure.
    • AddedPresence of clinical signs of heart failure.
    • AddedLVEF <40%.
    • EditedGlobal Exclusion CriteriaGeneral exclusion criteria:
    • RemovedOther associated lung pathology
    • RemovedOther heart disease
    • EditedContraindicationAllergy to MRI or echocardiography gel.
    • AddedSpecific exclusion criteria:
    • AddedHFpEF group:
    • AddedAssociated pulmonary disease.
    • AddedRegional wall motion abnormality.
    • AddedHFmrEF group:
    • Added- Associated pulmonary disease.
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedMyocardial rigiditystiffness assessment by elastographyTime frame: Day 1
    Secondary outcomes 2 added, 1 description edited
    What changed in the outcomes
    • AddedCharacterization of myocardial stiffness in patients with HFpEFTime frame: Day 1
    • AddedDiagnostic parameters of SWI in cardiac amyloidosisTime frame: Day 1
    • DescriptionNorms estimation of myocardial rigidity: how it is measured was reworded
    + 3 other changes: verification date, arm descriptions and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03895541
Lead sponsor
French Cardiology Society
Responsible party
Sponsor
First posted
Mar 29, 2019
Start date
Jan 24, 2020
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Oct 9, 2026

Study contacts

Emmanuel MESSAS, MD
Contact
emmanuel.messas@aphp.fr
33 6 65 03 85 02
Tessa BERGOT
Contact
tessa.bergot@sfcardio.fr
33 144907033
Emmanuel MESSAS, MD
principal investigator · Hopital Européen Georges Pompidou

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion